FGL2 and ovarian carcinoma: We next used the STOSE ovarian cancer model, as a more immunogenic model (expresses MHC-I in vivo) with a greater chance of responding to immunotherapy52, and targeted sFGL2 with the monoclonal α-FGL2 (clone 6H12).